Work

Correction to: Cenobamate: real-world data from a retrospective multicenter study

Year: 2024

Type: erratum

Abstract: Background Clinical trials have shown that cenobamate (CNB) is an efficacious and safe anti-seizure medication (ASM) for drug-resistant focal epilepsy.Here, we analyzed one of the largest real-world cohorts, covering the entire spectrum of epilepsy syndromes, the efficacy and safety of CNB, and resulting changes in concomitant ASMs. MethodsWe conducted a retrospective observational study investigating CNB usage in two German tertiary referral centers between October 2020 and June 2023 with followup data up to 27 months of treatment.Our primary outcome was treatment response.Secondary outcomes comprised drug response after 12 and 18 months, seizure freedom rates, CNB dosage and retention, adverse drug reactions (ADRs), and changes in concomitant ASMs.Results 116 patients received CNB for at least two weeks.At 6 months, 98 patients were eligible for evaluation.Thereof

Source: Journal of Neurology

Authors: Stephan Lauxmann, David Heuer, Jan Heckelmann, Florian P. Fischer, Melanie Schreiber, Elisabeth Schriewer, Guido Widman, Yvonne Weber, Holger Lerche, Michael Alber, Sigrid Schuh-Hofer, Stefan Wolking

Institutions: Hertie Institute for Clinical Brain Research, University of Tübingen, Universitätsklinikum Aachen, RWTH Aachen University, University Children's Hospital Tübingen

Language: English

Topic: Epilepsy research and treatment

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,590

OpenAlex ID: W4401753976

Cites:

Cited by: 1

Related to: 10